Inari Medical
NARI

Delisted

NARI was delisted on the 20th of February, 2025.

Back to rankings

About: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Employees: 1,300

Healthcare Surgical & Medical Instruments & Apparatus

Financial journalist opinion

If You Could Only Hold 3 Investments for Life, Consider These

Warren Buffett, who is known to own “forever stocks,” has famously quipped that if you aren't willing to own a stock for 10 years, you shouldn't own it for even 10 minutes.

If You Could Only Hold 3 Investments for Life, Consider These

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment.

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.

Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Shareholders to Inquire about Securities Investigation

Kadant Set to Join S&P SmallCap 600

NEW YORK , Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE: KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE: SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions.

Kadant Set to Join S&P SmallCap 600

Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Inari Medical, Inc. (NARI) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Inari Medical, Inc. (NARI) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.

Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Investors to Learn More About the Investigation

Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.

Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

See News Rankings

Charts implemented using Lightweight Charts™